GLPG-1837

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

GLPG-1837 (ABBV-974) 是一种有效的口服 CFTR 增强剂，对 F508del 和 G551D CFTR 的 EC50 分别为 3 nM 和 339 nM。

GLPG-1837 (ABBV-974)?is a potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively; shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor.Cystic Fibrosis,Phase 2 Clinical(In Vitro):GLPG1837 is a potent CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively. GLPG1837 increases the conductivity of the G551D CFTR channel with obtained potency of 181 nM. GLPG1837 is reversible CFTR potentiator, with a the apparent affinity within a range of 0.2～2 μM.

GLPG1837 is a potent CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively. GLPG1837 increases the conductivity of the G551D CFTR channel with obtained potency of 181 nM. GLPG1837 is reversible CFTR potentiator, with a the apparent affinity within a range of 0.2～2 μM.

——

GLPG1837 | GLPG 1837 | ABBV-974

Apoptosis

CFTR

F508delCFTR|G551DCFTR

Other Indications

Fibrosis

1654725-02-6

348.421

C16H20N4O3S

>98% (HPLC)

Ethanol: 5 mg/mL; Water: Insoluble; DMSO: 60 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(C1=NNC=C1)NC(S2)=C(C(N)=O)C3=C2C(C)(C)OC(C)(C)C3

N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide

(-20℃)

With Ice Pack

≥ 2 years